EMA's CHMP rejects Lecanemab MAA for early Alzheimer's treatment by Eisai and Biogen.
Eisai and Biogen announce disappointment over CHMP's negative opinion on Lecanemab MAA for early Alzheimer's disease treatment. The humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody was rejected by the European Medicines Agency's Committee for Medicinal Products for Human Use. The companies acknowledge the challenges of Alzheimer's disease and express their disappointment for the wider AD community.
July 26, 2024
3 Articles